

In one aspect of the present disclosure, there is provided a method of making an incretin analog of SEQ ID NO:6, the method comprising the step of:

coupling, via hybrid liquid solid phase synthesis, four intermediate compounds selected from the groups consisting of:

- 5 a. SEQ ID NOS:7, 8, 9 and 10,
 b. SEQ ID NOS:7, 11, 12, and 10, and
 c. SEQ ID NOS:7, 13, 14 and 10.

In another aspect of the present disclosure, there is provided a method of making an incretin analog of SEQ ID NO:6, the method comprising the step of:

10 coupling, via hybrid liquid solid phase synthesis, three intermediate compounds selected from the groups consisting of:

- a. SEQ ID NOS:7, 13 and 15,
 b. SEQ ID NOS:16, 17 and 10,
 c. SEQ ID NOS:18, 12 and 10, and
15 d. SEQ ID NOS:7, 45 and 10.

In another aspect of the present disclosure, there is provided a method of making an incretin analog of SEQ ID NO:6, the method comprising the step of:

coupling, via hybrid liquid solid phase synthesis, two intermediate compounds selected from the groups consisting of:

- 20 a. SEQ ID NOS:15 and 19 and
 b. SEQ ID NOS:18 and 20.

In another aspect of the present disclosure, there is provided a method of making an incretin analog of SEQ ID NO:29, the method comprising the step of:

coupling, via hybrid liquid solid phase synthesis, intermediate compounds selected from the groups consisting of:

- 5 a. SEQ ID NOS:7, 62, 42 and 31,
 b. SEQ ID NOS:43, and 44.

Description

In a first embodiment, the incretin analog can include an amino acid sequence of:

CLAIMS

The invention claimed is:

1. A method of making an incretin analog of SEQ ID NO:6, the method comprising
5 the step of:

coupling, via hybrid liquid solid phase synthesis, four intermediate compounds
selected from the groups consisting of:

- a. SEQ ID NOS:7, 8, 9 and 10,
b. SEQ ID NOS:7, 11, 12, and 10, and
10 c. SEQ ID NOS:7, 13, 14 and 10.

2. A method of making an incretin analog of SEQ ID NO:6, the method comprising
the step of:

coupling, via hybrid liquid solid phase synthesis, three intermediate compounds
15 selected from the groups consisting of:

- a. SEQ ID NOS:7, 13 and 15,
b. SEQ ID NOS:16, 17 and 10,
c. SEQ ID NOS:18, 12 and 10, and
20 d. SEQ ID NOS:7, 45 and 10.

3. A method of making an incretin analog of SEQ ID NO:6, the method comprising
the step of:

coupling, via hybrid liquid solid phase synthesis, two intermediate compounds
selected from the groups consisting of:

- 25 a. SEQ ID NOS:15 and 19 and
b. SEQ ID NOS:18 and 20.

4. A method of making an incretin analog of SEQ ID NO:29, the method
comprising the step of:

30 coupling, via hybrid liquid solid phase synthesis, intermediate compounds
selected from the groups consisting of:

- a. SEQ ID NOS:7, 62, 42 and 31,
b. SEQ ID NOS:43, and 44.